Osteoarthritis (OA) is a common, debilitating joint condition characterized by degeneration of cartilage. The early stages of OA feature synovial inflammation caused by sustained high levels of pro-inflammatory cytokines, which can be triggered by mechanical strain or age-related oxidative stress. Treatment options aim to reduce pain and improve function but do not affect disease progression. Some pharmacologic therapies, including nonsteroidal anti-inflammatory drugs, can cause side effects, and their long-term use poses safety concerns. LI73014F2 is a synergistic formulation of the extracts of chebulic myrobalan (Terminalia chebula, Combretaceae) fruit, turmeric (Curcuma longa, Zingiberaceae) rhizome, and boswellia (Boswellia serrata, Burseraceae) gum resin, which are used to treat inflammatory disorders in Ayurvedic medicine, in a 2:1:2 ratio. These authors conducted a placebo-controlled, double-blind trial to assess the clinical efficacy of two different doses of LI73014F2 on pain, joint stiffness, and mobility in patients with OA.

LI73014F2 was…